Pemetrexed for the treatment of non-small cell lung cancer. (Q38107552)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on 17 May 2013

Language	Label	Description	Also known as
English	Pemetrexed for the treatment of non-small cell lung cancer.	scientific article published on 17 May 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Pemetrexed for the treatment of non-small cell lung cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Giovanna Dal Bello

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Francesco Grossi

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Francesco Grossi

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Erika Rijavec

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Claudio Sini

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Giulia Barletta

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Grazia Savarino

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Francesco Boccardo

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

language of work or name

0 references

publication date

17 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Expert Opinion on Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1545-1558

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23683110%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Pemetrexed induces both intrinsic and extrinsic apoptosis through ataxia telangiectasia mutated/p53-dependent and -independent signaling pathways.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Pharmacokinetic evaluation of pemetrexed

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Pemetrexed safety and pharmacokinetics in patients with third-space fluid

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, r

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by mainte

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Management of non-small cell lung in cancer patients with stable disease.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Identifying an optimum treatment strategy for patients with advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis With the NVALT7 Trial

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Cost‐effectiveness of bevacizumab‐based therapy versus cisplatin plus pemetrexed for the first‐line treatment of advanced non‐squamous NSCLC in Korea and Taiwan

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.802774

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38107552&oldid=2134956029"